How similar is similar enough?

Advanced biotherapeutic characterization technologies from Waters help laboratories achieve the standards of regulatory bodies around the world: To produce sufficient analytical and biological evidence of similarity between innovator and biosimilar candidates that will reduce the clinical trial burden for approval. Because whether it's called a biosimilar, follow-on biologic, biogeneric, second-generation mAb, non-innovator protein, or even biobetter, the goal is the same: therapeutic safety and efficacy to improve patient health and wellness.

  • 개요
  • 상세설명
  • 관련내용
  • 라이브러리
  • 응용자료

연락처 보기